The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.

Xiaowei Xiong,Lu Hua,Dongxue Wang,Yishi Li,Hui Zhao,Hong Liu

doi:10.1186/s12944-015-0129-8

Abstract

BackgroundApolipoprotein CIII (apoCIII) is considered to impair the anti-atherogenic effect of high density lipoprotein (HDL) in coronary heart disease (CHD) patients, and apoCIII content in HDL (HDL-apoCIII) predicts CHD more accurately. However, the relationship between HDL-apoCIII and CHD, and the effect of statin treatment on HDL-apoCIII are still unclear. The aims of the study are to establish the association of HDL-apoCIII with CHD, and investigate the effect of statin treatment on HDL-apoCIII in CHD patients.MethodsWe conducted a hospital-based observational study. Totally 80 non-CHD patients and 120 CHD patients without statin treatment were previously enrolled in this study. All the CHD patients received statin treatment, and 63 of them were followed after 3 months of regular statin treatment. HDL sample of each patient was isolated by density gradient ultracentrifugation from fasting venous plasma, and HDL-apoCIII of each patient was measured by ELISA method.ResultsHDL-apoCIII was significantly higher in CHD patients than non-CHD patients (p < 0.05), and it was still an independent predictor of CHD after adjusting for other factors. Total plasma apoCIII, especially HDL-apoCIII was significantly elevated after statin treatment in CHD patients, whereas total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) and apolipoprotein B (apoB) were decreased significantly (p < 0.05). Compared with CHD patients without diabetes mellitus (DM), the effect of statin treatment on apoCIII markers was minor in CHD patients with DM. And HDL-apoCIII correlated with plasma TG significantly in non-CHD and CHD patients (p < 0.05), but the correlation in CHD patients did not exist after statin treatment (p > 0.05).ConclusionsHDL-apoCIII has a significant and positive association with CHD. Although conventional atherogenic lipid markers have a significantly decrease in CHD patients after statin treatment, HDL-apoCIII has a further elevation at the same time.Electronic supplementary materialThe online version of this article (doi:10.1186/s12944-015-0129-8) contains supplementary material, which is available to authorized users.

Highlights

Coronary heart disease (CHD) is a chronic inflammatory disease characterized with dyslipidemia [1,2,3]
There was no significant difference of total plasma Apolipoprotein CIII (apoCIII) between two groups (p > 0.05), but high density lipoprotein (HDL)-apoCIII was significantly higher in CHD patients than non-CHD patients (p < 0.01)
In order to identify the relationship between HDLapoCIII and CHD, we analyzed the associations between various lipid markers and CHD by multivariate logistic regression analysis (Table 2)

Summary

Introduction

Coronary heart disease (CHD) is a chronic inflammatory disease characterized with dyslipidemia [1,2,3] Conventional lipid markers such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) are considered to associate with CHD positively or. Lipid-lowering drugs, statins were demonstrated to reduce the progression of CHD and cardiovascular event significantly by decreasing atherogenic lipids [19, 20] To date, it is still unclear if statin treatment has the same effect on HDL-apoCIII in CHD patients. Apolipoprotein CIII (apoCIII) is considered to impair the anti-atherogenic effect of high density lipoprotein (HDL) in coronary heart disease (CHD) patients, and apoCIII content in HDL (HDL-apoCIII) predicts CHD more accurately. The aims of the study are to establish the association of HDL-apoCIII with CHD, and investigate the effect of statin treatment on HDL-apoCIII in CHD patients

Objectives

Results

Discussion

Conclusion